Forum Topic News
  • Conversation: FDA Approves Pfizer and Merck's Ertugliflozin for Type 2 Diabetes

    • December 21, 2017 12:44 PM GMT
      • Post(s)
        568

      FDA Approves Pfizer and Merck's Ertugliflozin for Type 2 Diabetes

      The US Food and Drug Administration (FDA) has approved ertugliflozin (Steglatro) for the treatment of glycemic control in patients with type 2 diabetes (T2D).
      Ertugliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor from Merck & Co. and Pfizer, was approved as both a single therapy and fixed-dose combination therapy with dipeptidyl peptidase-4 inhibitor sitagliptin (Januvia) or common first-line therapy metformin. The combination therapies will carry the brand names Steglujan and Segluromet, respectively.
      Merck and Pfizer previously announced successfully-met endpoints for the combination therapies in 2 phase 3 trials (VERTIS MET, VERTIS SITA) in June.
      Read more: http://bit.ly/ErtuglifozinApproval

Add Reputation

Do you want to add reputation for this member by this post?

or cancel
‚Äč